Literature DB >> 22457518

Reconstruction of human papillomavirus type 16-mediated early-stage neoplasia implicates E6/E7 deregulation and the loss of contact inhibition in neoplastic progression.

Erin Isaacson Wechsler1, Qian Wang, Ian Roberts, Emilio Pagliarulo, Deborah Jackson, Christina Untersperger, Nick Coleman, Heather Griffin, John Doorbar.   

Abstract

Infection with human papillomavirus type 16 (HPV-16) can lead to low- or high-grade squamous intraepithelial lesions (LSIL or HSIL). Here we show that these in vivo disease states can be replicated in raft cultures of early-pass HPV-16 episomal cell lines, at both the level of pathology and the level of viral gene expression. A reduced responsiveness to cell-cell contact inhibition and an increase in E6/E7 activity correlated closely with phenotype. Similar deregulation is likely to underlie the appearance of LSIL or HSIL soon after infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22457518      PMCID: PMC3372204          DOI: 10.1128/JVI.07069-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS.

Authors:  B L Allen-Hoffmann; S J Schlosser; C A Ivarie; C A Sattler; L F Meisner; S L O'Connor
Journal:  J Invest Dermatol       Date:  2000-03       Impact factor: 8.551

2.  Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts.

Authors:  N Häfner; C Driesch; M Gajda; L Jansen; R Kirchmayr; I B Runnebaum; M Dürst
Journal:  Oncogene       Date:  2007-09-10       Impact factor: 9.867

3.  Improved cervical smear assessment using antibodies against proteins that regulate DNA replication.

Authors:  G H Williams; P Romanowski; L Morris; M Madine; A D Mills; K Stoeber; J Marr; R A Laskey; N Coleman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

4.  Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes.

Authors:  R Klaes; S M Woerner; R Ridder; N Wentzensen; M Duerst; A Schneider; B Lotz; P Melsheimer; M von Knebel Doeberitz
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

5.  Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18.

Authors:  A Szarewski; W A J Poppe; S R Skinner; C M Wheeler; J Paavonen; P Naud; J Salmeron; S-N Chow; D Apter; H Kitchener; X Castellsagué; J C Teixeira; J Hedrick; U Jaisamrarn; G Limson; S Garland; B Romanowski; F Y Aoki; T F Schwarz; F X Bosch; D M Harper; K Hardt; T Zahaf; D Descamps; F Struyf; M Lehtinen; G Dubin
Journal:  Int J Cancer       Date:  2011-10-23       Impact factor: 7.396

6.  Human scribble, a novel tumor suppressor identified as a target of high-risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous polyposis coli.

Authors:  Shin Takizawa; Kazunori Nagasaka; Shunsuke Nakagawa; Tetsu Yano; Keiichi Nakagawa; Toshiharu Yasugi; Takamasa Takeuchi; Tadahito Kanda; Jon M Huibregtse; Tetsu Akiyama; Yuji Taketani
Journal:  Genes Cells       Date:  2006-04       Impact factor: 1.891

7.  Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

Authors:  J Paavonen; P Naud; J Salmerón; C M Wheeler; S-N Chow; D Apter; H Kitchener; X Castellsague; J C Teixeira; S R Skinner; J Hedrick; U Jaisamrarn; G Limson; S Garland; A Szarewski; B Romanowski; F Y Aoki; T F Schwarz; W A J Poppe; F X Bosch; D Jenkins; K Hardt; T Zahaf; D Descamps; F Struyf; M Lehtinen; G Dubin
Journal:  Lancet       Date:  2009-07-06       Impact factor: 79.321

Review 8.  Molecular biology of human papillomavirus infection and cervical cancer.

Authors:  John Doorbar
Journal:  Clin Sci (Lond)       Date:  2006-05       Impact factor: 6.124

9.  Minichromosome maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulval intraepithelial neoplasia.

Authors:  E J Davidson; L S Morris; I S Scott; S M Rushbrook; K Bird; R A Laskey; G E Wilson; H C Kitchener; N Coleman; P L Stern
Journal:  Br J Cancer       Date:  2003-01-27       Impact factor: 7.640

10.  Life cycle heterogeneity in animal models of human papillomavirus-associated disease.

Authors:  Woei Ling Peh; Kate Middleton; Neil Christensen; Philip Nicholls; Kiyofumi Egawa; Karl Sotlar; Janet Brandsma; Alan Percival; Jon Lewis; Wen Jun Liu; John Doorbar
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more
  31 in total

1.  E5 can be expressed in anal cancer and leads to epidermal growth factor receptor-induced invasion in a human papillomavirus 16-transformed anal epithelial cell line.

Authors:  Erin Isaacson Wechsler; Sharof Tugizov; Rossana Herrera; Maria Da Costa; Joel M Palefsky
Journal:  J Gen Virol       Date:  2018-04-06       Impact factor: 3.891

Review 2.  The human papillomavirus E7 oncoprotein as a regulator of transcription.

Authors:  William K Songock; Seong-Man Kim; Jason M Bodily
Journal:  Virus Res       Date:  2016-11-08       Impact factor: 3.303

Review 3.  Human papillomavirus molecular biology.

Authors:  Mallory E Harden; Karl Munger
Journal:  Mutat Res Rev Mutat Res       Date:  2016-07-05       Impact factor: 5.657

4.  The Nuclear DNA Sensor IFI16 Acts as a Restriction Factor for Human Papillomavirus Replication through Epigenetic Modifications of the Viral Promoters.

Authors:  Irene Lo Cigno; Marco De Andrea; Cinzia Borgogna; Silvia Albertini; Manuela M Landini; Alberto Peretti; Karen E Johnson; Bala Chandran; Santo Landolfo; Marisa Gariglio
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

5.  Quantitative measurement of human papillomavirus type 16 e5 oncoprotein levels in epithelial cell lines by mass spectrometry.

Authors:  Ziad Sahab; Sawali R Sudarshan; Xuefeng Liu; YiYu Zhang; Alexander Kirilyuk; Christopher M Kamonjoh; Vera Simic; Yuhai Dai; Stephen W Byers; John Doorbar; Frank A Suprynowicz; Richard Schlegel
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

6.  Therapeutic efficacy of a human papillomavirus type 16 E7 bacterial exotoxin fusion protein adjuvanted with CpG or GPI-0100 in a preclinical mouse model for HPV-associated disease.

Authors:  Diane M Da Silva; Joseph G Skeate; Elena Chavez-Juan; Kim P Lühen; Jiun-Ming Wu; Chia-Mao Wu; W Martin Kast; KinKai Hwang
Journal:  Vaccine       Date:  2019-04-19       Impact factor: 3.641

7.  The transcription factors TBX2 and TBX3 interact with human papillomavirus 16 (HPV16) L2 and repress the long control region of HPVs.

Authors:  Marc A Schneider; Konstanze D Scheffer; Timo Bund; Fatima Boukhallouk; Carsten Lambert; Cristina Cotarelo; Gert O Pflugfelder; Luise Florin; Gilles A Spoden
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

8.  Regulation of the human papillomavirus type 16 late promoter by E7 and the cell cycle.

Authors:  Jason M Bodily; Christine Hennigan; Gary A Wrobel; Cynthia M Rodriguez
Journal:  Virology       Date:  2013-05-29       Impact factor: 3.616

9.  Human Papillomavirus E2 Regulates SRSF3 (SRp20) To Promote Capsid Protein Expression in Infected Differentiated Keratinocytes.

Authors:  T Klymenko; H Hernandez-Lopez; A I MacDonald; J M Bodily; S V Graham
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

10.  Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM.

Authors:  Heather Griffin; Yasmina Soneji; Romy Van Baars; Rupali Arora; David Jenkins; Miekel van de Sandt; Zhonglin Wu; Wim Quint; Robert Jach; Krzysztof Okon; Hubert Huras; Albert Singer; John Doorbar
Journal:  Mod Pathol       Date:  2015-05-08       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.